Italian Competition Authority has initiated an investigation against several major players of pharmaceutical sector including Novartis, Genentech, Biogen and Samsung Bioepis. AGCM contended that these companies colluded to eliminate competition for a biosimilar of the drug lucentis. Further, AGCM alleges that these companies came together and delayed the launch of Byooviz in Italy, the Netherlands and the U.K. Such investigation shows commitment of AGCM to protect competition in pharmaceutical sector.
